TLDR

Hyperbaric oxygen therapy (HBOT) is generally safe and clinically beneficial for cancer patients undergoing chemotherapy — when properly timed, screened, and coordinated with the oncology team. Two drugs require a hard stop and oncology clearance before any HBOT session: Bleomycin (pulmonary toxicity risk) and Doxorubicin/Adriamycin (cardiac oxidative stress risk). Several other agents require close monitoring and careful scheduling. Beyond safety, the evidence shows HBOT reduces treatment-related fatigue, nausea, and neuropathy; supports immune function and DNA repair; and normalizes tumor hypoxia in ways that may actually enhance the effectiveness of chemotherapy and radiation.

Table of Contents

• Is HBOT safe during chemotherapy?
• Which chemo drugs are contraindicated with HBOT?
• Which drugs require caution and close monitoring?
• What is the right timing protocol for HBOT during chemo?
• Why is oncology team coordination essential?
• What are the clinical benefits of HBOT during cancer treatment?
• Does HBOT make cancer worse — or could it help?
• Can HBOT be combined with red light therapy (PBM) during treatment?
• How OxygenWell approaches cancer support

Is HBOT Safe During Chemotherapy?

The short answer: yes, for most patients and most chemotherapy regimens — with proper screening. This is one of the most common questions cancer patients ask when they first learn about integrative oncology protocols, and the concern is understandable. You are managing a serious illness, and the last thing you want is for one treatment to interfere with another.

At OxygenWell, we review every patient's full medication list, oncology history, and current treatment phase before a single session begins. Our physician-led team, with over 50,000 supervised HBOT sessions and 12+ years dedicated to hyperbaric medicine in Los Angeles, has developed protocols that take the complexity of active chemotherapy seriously.

The key insight is this: HBOT is not inherently incompatible with chemotherapy. It is incompatible with specific agents under specific circumstances. Once those are identified, HBOT becomes a powerful tool to support the body during one of its most demanding challenges.

A 2025 safety evaluation published in Medicina (Kaunas) confirmed that HBOT can be used safely in cancer patients when contraindications are respected and sessions are coordinated with the treating oncology team. [PMC, 2025]

Which Chemotherapy Drugs Are Contraindicated With HBOT?

Two agents carry a firm contraindication. HBOT should not proceed until the patient has stopped these drugs and obtained explicit clearance from their oncologist.

1. Bleomycin — Pulmonary Toxicity Risk

Bleomycin, used commonly in lymphoma and germ cell tumors (testicular, ovarian), generates reactive oxygen species (ROS) as part of its mechanism of action. In normal circumstances, the lung has some tolerance for this oxidative load. Under hyperbaric oxygen conditions, the concentration of oxygen dramatically increases, which can amplify Bleomycin's ROS activity in lung tissue and trigger severe — sometimes fatal — pulmonary toxicity.

This is not a theoretical risk. It is documented in the literature and recognized as an absolute contraindication by StatPearls and the Undersea and Hyperbaric Medical Society (UHMS). [StatPearls, Hyperbaric Contraindicated Chemotherapeutic Agents]

Clinical rule: No HBOT on the same day as Bleomycin administration. Do not proceed at all until the patient's oncologist confirms it is safe to reintroduce HBOT.

2. Doxorubicin (Adriamycin) — Cardiac Oxidative Stress Risk

Doxorubicin is one of the most widely used chemotherapy agents, prescribed for breast cancer, lymphoma, leukemia, sarcoma, and others. It works in part by generating free radicals — and its well-known cardiotoxicity is mediated by oxidative stress in cardiac tissue. Introducing hyperbaric oxygen during active Doxorubicin treatment risks amplifying that oxidative burden on the heart, potentially worsening cardiac injury.

Patients who have completed Doxorubicin treatment may be candidates for HBOT, but only after full review of cardiac function and a clearance conversation with their oncologist.

Clinical rule: No HBOT during active Doxorubicin/Adriamycin therapy without explicit oncology clearance. This rule applies even for patients on maintenance or low-dose Adriamycin regimens.

Which Chemotherapy Drugs Require Caution and Monitoring?

The following agents do not carry an absolute contraindication, but they require careful scheduling, close clinical monitoring, and coordination with the patient's oncology team before and during HBOT. Sessions should never occur on the same day as administration of these agents, and the patient's labs and symptoms need to be reviewed between cycles.

Cisplatin and Carboplatin — Nephrotoxicity and Ototoxicity

Both platinum-based agents carry risks for kidney damage (nephrotoxicity) and hearing loss (ototoxicity). HBOT's effects on circulation and renal perfusion can interact with these toxicities. Monitoring kidney function, electrolytes, and hearing before and during an HBOT course is essential. Never schedule HBOT on the same day as Cisplatin or Carboplatin infusion.

Methotrexate — Tissue Toxicity and Mucositis

Methotrexate can cause significant tissue toxicity, mucositis, and impaired wound healing. HBOT's pro-healing effects can generally be beneficial here, but timing is critical: introducing HBOT too close to Methotrexate administration can stress already inflamed mucosal tissue. Careful scheduling around the patient's infusion calendar and mucositis status is required.

Etoposide — Myelosuppression

Etoposide suppresses bone marrow function, lowering white blood cell counts and increasing infection risk. HBOT has immune-modulating properties, but patients with active myelosuppression need careful assessment of infection risk before entering the hyperbaric environment. Review of CBC and absolute neutrophil count prior to sessions is standard protocol.

Cyclophosphamide — Bladder Toxicity

Cyclophosphamide carries a risk of hemorrhagic cystitis — inflammation and bleeding in the bladder. Because HBOT is actually a highly effective treatment for radiation-induced cystitis and can support bladder healing, the interaction here is nuanced. The key is avoiding HBOT when active bladder irritation is present from Cyclophosphamide, and always coordinating timing carefully to avoid compounding toxicity.

What Is the Right Timing Protocol for HBOT During Chemotherapy?

Timing is everything. At OxygenWell, we use a structured three-phase protocol for patients in active chemotherapy, calibrated to the biology of each treatment cycle.

Before Each Chemotherapy Cycle: Prehabilitation (2 to 5 Sessions)

• Pressure: 1.3 to 2.0 ATA
• Duration: 60 to 90 minutes per session
• Goal: Saturate tissues with oxygen before the oxidative and inflammatory stress of chemotherapy. HBOT at this phase increases mitochondrial ATP production, mobilizes CD34+ stem cells, and reduces baseline inflammatory cytokines (CRP, TNF-alpha, IL-6). This prepares the body to absorb the treatment with greater resilience.

After Each Chemotherapy Cycle: Recovery (1 to 3 Sessions, 24 to 72 Hours Post-Infusion)

• Pressure: 1.3 to 2.0 ATA
• Duration: 60 to 90 minutes per session
• Goal: Support detoxification and accelerate recovery. The 24 to 72-hour window after chemotherapy is ideal: the peak drug concentration has passed, but the inflammatory cascade and oxidative stress are still active. HBOT at this phase upregulates antioxidant defenses (SOD, Glutathione), supports liver detox pathways, reduces treatment fatigue, and helps the immune system recover.

Between Cycles: Maintenance (1 to 2 Sessions Per Week)

• Pressure: 1.3 to 2.0 ATA
• Duration: 60 to 90 minutes per session
• Goal: Sustain the benefits between active treatment. These maintenance sessions keep angiogenesis progressing, support ongoing immune balance, and prevent the cumulative fatigue that builds across multiple chemo cycles.

OxygenWell's FDA-cleared chambers operate up to 2.4 ATA with 100% medical-grade oxygen — well above the 1.3 to 2.0 ATA range used during active chemo support — giving our clinical team the full therapeutic range needed to individualize protocols based on each patient's response.

Why Is Oncology Team Coordination Essential?

No integrative therapy should operate in isolation from the patient's primary cancer care team. This is not a formality — it is a clinical necessity.

The oncologist knows the patient's full treatment regimen, upcoming dosing schedule, current blood counts, organ function status, and any emerging toxicities. The hyperbaric physician needs this information to make safe, individualized decisions about when to proceed, when to pause, and how to adjust the HBOT protocol in real time.

At OxygenWell, we work alongside the patient's oncologist as a collaborative partner in care. We do not replace or compete with conventional oncology. Our position is clear: HBOT is an adjunct to conventional cancer care, not a replacement.

Practically, this coordination involves:

• A full medication and chemotherapy review before starting HBOT
• A signed consent process that includes oncology awareness
• Real-time communication with the treating oncologist when drug lists change
• Adjustment of HBOT scheduling around infusion calendars and lab results

What Are the Clinical Benefits of HBOT During Cancer Treatment?

When properly timed and screened, hyperbaric oxygen therapy offers a meaningful set of benefits for patients in active cancer treatment.

Reduction in Fatigue and Improved Quality of Life

Cancer-related fatigue is one of the most debilitating side effects of chemotherapy, affecting up to 90% of patients. A meta-analysis published in Support Care Cancer (2016) found that HBOT significantly improves quality of life and reduces fatigue in cancer patients. [Support Care Cancer, 2016]

Reduction in Nausea and Chemotherapy-Induced Neuropathy

HBOT's anti-inflammatory and neuroregenerative properties support peripheral nerve health, which is directly relevant to chemotherapy-induced peripheral neuropathy (CIPN) — a common and often lasting side effect of agents like Cisplatin, Oxaliplatin, and Taxanes. HBOT increases nerve oxygenation, reduces neuroinflammation, and upregulates BDNF (brain-derived neurotrophic factor), supporting nerve repair and reducing neuropathic symptoms.

Immune Function Support

Chemotherapy suppresses the immune system — the same system the body relies on to fight residual cancer cells and prevent infection. HBOT modulates immune function, supporting NK cell activity, reducing pathological inflammation, and balancing cytokine profiles. Research published via StatPearls (2023) confirms HBOT enhances immune function and may improve tumor oxygenation. [Thom and Bhopale, StatPearls, 2023]

DNA Repair and Cellular Recovery

Chemotherapy damages DNA — in cancer cells, which is the intent, but also in healthy cells, which is the cost. HBOT supports DNA repair mechanisms by reducing oxidative markers (8-OHdG, MDA), upregulating antioxidant enzymes (SOD, Glutathione), and improving mitochondrial function. Research from March (2016) demonstrates HBOT improves mitochondrial function and reduces oxidative stress — both directly relevant to cellular recovery during and after chemotherapy.

Radiation-Induced Tissue Damage

For patients receiving concurrent radiation therapy, HBOT has a strong evidence base. StatPearls (2023) confirms HBOT reduces radiation-induced tissue damage and promotes healing in affected tissues — including radiation cystitis, osteoradionecrosis, and soft tissue radionecrosis. These are FDA-approved, insurance-covered indications.

Does HBOT Make Cancer Worse — or Could It Help?

This is the question many patients and families carry into their first consultation. The concern is logical: if cancer thrives, might feeding it more oxygen accelerate its growth?

The current scientific evidence does not support this concern. It points in the opposite direction.

Tumors thrive in hypoxic (oxygen-deprived) environments. Hypoxia promotes tumor aggressiveness, metastatic behavior, and resistance to both chemotherapy and radiation — precisely because many cancer drugs and radiation rely on the presence of oxygen to generate cell-killing reactive oxygen species.

HBOT normalizes tumor hypoxia. By restoring adequate oxygenation to the tumor microenvironment, HBOT may enhance the effectiveness of chemotherapy and radiation. A 2025 review in Biomedicine and Pharmacotherapy concluded that "HBOT alleviates tumor hypoxia and enhances the sensitivity of chemotherapy, radiotherapy, and immunotherapy." [Biomedicine and Pharmacotherapy, 2025]

A 2021 study published in Scientific Reports (Nature) found that HBOT not only improved tumor hypoxia but also suppressed tumor growth in lung cancer xenograft models — the opposite of promoting cancer. [Scientific Reports, Nature, 2021]

OxygenWell's clinical safety statement, grounded in the current literature: Current evidence does not show HBOT promotes cancer growth.

This is also a core principle in the Metabolic Approach to Cancer: cancer thrives in dysfunctional terrain — hypoxia, mitochondrial dysfunction, chronic inflammation, immune dysregulation, oxidative stress, and impaired detoxification. HBOT restores the terrain, which is hostile to cancer and supportive of healthy tissue recovery.

Can HBOT Be Combined With Red Light Therapy (PBM) During Treatment?

Yes — and at OxygenWell, we offer a combined HBOT and Photobiomodulation (PBM) protocol specifically designed for cancer patients and post-surgical recovery.

PBM uses targeted red and near-infrared light to stimulate mitochondrial recovery and reduce inflammation at the cellular level:

• Red light (630 to 660 nm): Superficial healing, lymphatic support, inflammation reduction
• Near-infrared (810 to 880 nm): Deeper mitochondrial and systemic recovery

PBM is generally safe during chemotherapy when applied appropriately — with direct application avoided over active tumor sites. The ideal timing aligns with the HBOT recovery window: 24 to 72 hours after chemotherapy. PBM can also be used between cycles for maintenance, and in lower-intensity formats on the same day as treatment when clinically appropriate.

The combination of HBOT and PBM creates a compounding effect on mitochondrial function, cellular oxygenation, and anti-inflammatory signaling — making the two therapies more effective together than either is alone.

How OxygenWell Approaches Cancer Support

OxygenWell is a physician-owned hyperbaric and regenerative medicine clinic with locations in Sherman Oaks and Calabasas, California. Founded by Dr. Beth Meneley, DAOM, L.Ac., OxygenWell brings 25+ years in integrative medicine, 12+ years dedicated to hyperbaric medicine in Los Angeles, and 50,000+ supervised HBOT sessions to every patient consultation.

California law requires hyperbaric facilities to be physician-owned — a safety and accountability standard that most centers in the region do not meet. OxygenWell meets it by design. Our Fortius 420 chambers are FDA-cleared to 2.4 ATA and operate on 100% medical-grade oxygen delivered through a high-flow system, not a standard oxygen concentrator.

For cancer patients, our approach integrates HBOT's published evidence base with the Terrain Model of cancer care — addressing the five pillars of health that cancer disrupts: Oxygenation, Inflammation Control, Detoxification, Mitochondrial Function, and Immune Balance.

We accept Medicare and PPO insurance for FDA-approved conditions, including radiation-induced tissue injuries. Our billing team handles all pre-authorizations. We offer evening and weekend hours to accommodate patients whose treatment schedules make weekday appointments difficult.

Ready to Explore HBOT During Chemotherapy?

If you are currently undergoing or planning chemotherapy and want to explore how HBOT can support your body through treatment, the first step is a consultation with our clinical team. We will review your full treatment plan, medication list, and health status to determine whether HBOT is appropriate, which protocol fits your current phase, and how to coordinate safely with your oncology team.

Call us at (818) 661-0939 or visit www.oxygenwell.com. We serve patients throughout Sherman Oaks, Calabasas, and the greater Los Angeles area, with hours that include evenings and weekends.

About the Author: Dr. Beth Meneley, DAOM, L.Ac., is the Founder of OxygenWell Hyperbaric and Regenerative Medicine Center in Sherman Oaks and Calabasas, CA. With 25+ years in integrative medicine, 12+ years dedicated to hyperbaric medicine in Los Angeles, and 50,000+ supervised HBOT sessions, she is one of Southern California's leading voices in integrative oncology and hyperbaric medicine. OxygenWell is a physician-owned, FDA-cleared facility accepting Medicare and PPO insurance for approved conditions.

Clinical References

• Baude J, Cooper JS. Hyperbaric Contraindicated Chemotherapeutic Agents. StatPearls. NCBI Bookshelf. 2023. ncbi.nlm.nih.gov/books/NBK560873
• Gawdi R, Yrastorza J, Cooper JS. Hyperbaric Oxygen Therapy Contraindications. StatPearls. NCBI Bookshelf. 2023. ncbi.nlm.nih.gov/books/NBK557661
• Thom SR, Bhopale VM. Hyperbaric oxygen therapy: enhancing immune function and tumor oxygenation. StatPearls. 2023.
• Support Care Cancer. HBOT improves quality of life and reduces fatigue in cancer patients. Meta-analysis. 2016.
• March B. HBOT improves mitochondrial function and reduces oxidative stress. 2016.
• Meng Y et al. Breaking the hypoxia barrier: Advances and challenges of hyperbaric oxygen therapy in cancer treatment. Biomedicine and Pharmacotherapy. 2025. doi:10.1016/j.biopha.2025.118703
• Arslan KC et al. Hyperbaric Oxygen Therapy for Managing Cancer Treatment Complications: A Safety Evaluation. Medicina (Kaunas). 2025;61(3):385. PMC11943617
• Hyperbaric oxygen suppressed tumor progression through improvement of tumor hypoxia and induction of tumor apoptosis in lung cancer. Scientific Reports. Nature. 2021. nature.com